The Daily Signal
Culture

Fentanyl Killed 300,000 While Boxing Narratives Stayed Still

Victor·Wednesday, July 15, 2026 Edition
When Metaphors Outlive Their Moment

André Holland's character Walt is a former boxer living in Washington DC, trying to reclaim something from his past.

The film wraps this in the familiar shape we know. The gritty urban setting, the mentor figure, the ring as redemption. It's a shape that worked for Creed in 2015 and for Million Dollar Baby in 2004.

Holland's performance carries warmth into a harsh world and the boxing metaphor holds. We've seen this before and it still moves us, but the "before" matters more than the film seems to know.

When the metaphor breaks

When Million Dollar Baby arrived, deindustrialization had already hollowed the Rust Belt for two decades. Ryan Coogler made Creed in 2015 as the post-2008 precariat was learning to call itself gig work. Both films positioned boxing as the last available lever for restoring male identity and economic standing when industrial work had vanished. The ring was what remained when the factory closed.

They Fight arrives after a decade in which the ground shifted again. Between Creed and now, fentanyl has killed nearly 300,000 Americans. Algorithmic labor has made precarity not occasional but structural, not a phase but an identity. The economic moment that made boxing redemption narratives legible has calcified into something harder and stranger. Individual willpower is no longer insufficient. It's actively beside the point when your obstacle isn't identity loss but pharmaceutical addiction or a routing algorithm.

If They Fight retreats to the individual-overcomes-trauma script without acknowledging this shift, it's not recycling a tired metaphor. It's actively obscuring why that metaphor no longer fits the communities it claims to represent. It's using their story to tell an older, easier story instead.

Watch whether the film treats the DC drug trade as backdrop or as system. That distinction determines whether this is cinema about working-class struggle or cinema for audiences who want the aesthetic of struggle without its actual anatomy. Your own work asks the same question. Are you responding to what's actually happening now, or using current materials to tell old stories about how change happens?

Related Stories
Culture
Jackson's 2001 Precedent Shields Future All-White Casts
The article argues that Peter Jackson established a self-protecting pattern in 2001 by casting all-white heroes, then justifying it as faithfulness to source ma
Culture
Lee Ryan's Minor Assault Costs More Than Chris Brown's
Famous people absorb legal consequences without career damage because audience size insulates them from material loss, while semi-famous people face harder puni
HumanPotential
Motown's 1966 Studio Mistake Created Intimacy
A technical error that isolated Marvin Gaye's vocal on "I Heard It Through the Grapevine" produced something more human than the intended orchestrated version.
More From Today's Edition
Science
Ten Percent Left-Handedness Needs No Explanation
The article argues that left-handedness persists at a stable 10% not because evolution optimized it, but because it's developmental noise with no adaptive cost—
Film
Barbican Exhibits Pan-Africanism Only After Its Defeat
Institutions neutralize radical movements by waiting decades until their political demands become safely historical, then exhibiting them as prestige content st
Technology
Google Opens Play Store to Rivals July 22nd
Forcing a gatekeeper to open doors doesn't automatically create viable alternatives—only attention and user momentum do. Epic won the lawsuit but won't profit a
Technology
Noom's $60 Monthly Gamble Built on Three-Month Churn
Noom's business model depends on perpetual discounting and churn rather than product efficacy—the company acquires users with half-price promotions, loses them
Technology
OpenAI Researcher's $2B Startup Chases Speed, Misses Clinical Reality
AI drug discovery startups are optimizing for computational speed—a measurable problem they can showcase to investors—while ignoring Phase 2 clinical failure, t
View Past Editions >